Bioxytran (OTCMKTS:BIXT – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.02) EPS for the quarter, Zacks reports.
Bioxytran Stock Down 5.2%
OTCMKTS:BIXT traded down $0.00 during mid-day trading on Friday, hitting $0.03. 4,000 shares of the stock traded hands, compared to its average volume of 83,667. The stock has a market capitalization of $3.74 million, a price-to-earnings ratio of -1.65 and a beta of 1.95. Bioxytran has a 52 week low of $0.03 and a 52 week high of $0.17. The firm’s 50 day moving average is $0.04 and its two-hundred day moving average is $0.05.
Bioxytran Company Profile
Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.
Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.
Recommended Stories
- Five stocks we like better than Bioxytran
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
